Blood · 2012 · 180 citations · 16 references
MedicineCancer BiologyOncologyHematologic OncologyOncogenesTumor MicroenvironmentCancer ImmunotherapyHematologic Malignancy TherapyMultiple MyelomaMyc Family OncogenesOncogene AddictionC-myc RegulationMyc OverexpressionMyeloma Pathogenesis
In multiple myeloma, c-MYC is activated and contributes to the malignant phenotype. Targeting MYC by short hairpin RNA induced cell death in myeloma cell lines; however, cell lines are generated from samples taken in advanced stages of the disease and may not reflect patient cells adequately. In this study, we used the selective small molecule inhibitor of MYC-MAX heterodimerization, 10058-F4, on myeloma cell lines as well as primary myeloma cells, and we show that inhibition of c-MYC activity efficiently induces myeloma cell death. Moreover, in cocultures of cell lines with bone marrow stromal cells from myeloma patients, the inhibitor still induces apoptosis. Our results provide further evidence that myeloma cells are addicted to c-MYC activity and that c-MYC is a promising therapeutic target in multiple myeloma.
16
BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
Jake Delmore, Ghayas C. Issa, Madeleine E. Lemieux et al. · Cell · 2011 · 2.8K citations · Full text
IRF4 addiction in multiple myeloma
Arthur L. Shaffer, N. C. Tolga Emre, Laurence Lamy et al. · Nature · 2008 · 728 citations · Full text
Medicine, Cancer Biology, Oncology +11
Low molecular weight inhibitors of Myc–Max interaction and function
Xiaoying Yin, Christine Giap, John S. Lazo et al. · Oncogene · 2003 · 430 citations